Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m).
Andrea MarshallMark LevineCatherine HillDanielle HaleJenny ThirlwallVeronica WilkieKaren FrenchAjay KakkarAnand LokareAnthony MaraveyasOliver ChapmanAzra ArifStavros PetrouMandy MaredzaRichard HobbsJanet A DunnAnnie M YoungPublished in: Journal of thrombosis and haemostasis : JTH (2020)
The SELECT-D trial was underpowered to detect a statistically significant reduction in recurrent VTE with extended anticoagulation. The absence of RDVT and/or index PE, defined a population at low risk of recurrence.